Philips Receives FDA Clearance for Image-Guided Prostate Cancer Solution
The newly cleared platform combines MR and ultrasound imaging to support real-time guidance for focal therapy and improve clinical accuracy.
The newly cleared platform combines MR and ultrasound imaging to support real-time guidance for focal therapy and improve clinical accuracy.
EDAP TMS has announced that its Focal One HIFU device received approval from Health Canada in January 2015, which authorizes the company to market the device for the treatment of prostate cancer throughout Canada.
The newly cleared platform combines MR and ultrasound imaging to support real-time guidance for focal therapy and improve clinical accuracy.